OBJECTIVES: To compare the advantages to patients and to programmes between fixed-dose combination (FDC) antiretroviral therapy and separate tablet regimens. METHODS: Three electronic databases and two conference abstract sites were searched from inception to 01 March 2013 without geographical, language or date limits. Studies were included if they reported data on clinical outcomes, patient-reported outcomes and programme-related outcomes that could be related to pill burden for adult and adolescent patients on ART. For the primary outcomes of adherence and virological suppression, relative risks and 95% confidence intervals were calculated, and these were pooled using random effects meta-analysis. RESULTS: Twenty-one studies including information on 27,230 subjects were reviewed. Data from randomised trials showed better adherence among patients receiving FDCs than among patients who did not (relative risk 1.10, 95%CI 0.98-1.22); these findings were consistent with data from observational cohorts (RR 1.17, 95% CI 1.07-1.28). There was also a tendency towards greater virological suppression among patients receiving FDCs in randomised trials (RR 1.04, 95%CI 0.99-1.10) and observational cohort studies (RR 1.07, 95% CI 0.97-1.18). In all studies reporting patient preference, FDCs were preferred. The overall quality of the evidence was rated as low. CONCLUSIONS: Fixed-dose combinations appear to offer multiple advantages for programmes and patients, particularly with respect to treatment adherence.
OBJECTIVES: To compare the advantages to patients and to programmes between fixed-dose combination (FDC) antiretroviral therapy and separate tablet regimens. METHODS: Three electronic databases and two conference abstract sites were searched from inception to 01 March 2013 without geographical, language or date limits. Studies were included if they reported data on clinical outcomes, patient-reported outcomes and programme-related outcomes that could be related to pill burden for adult and adolescent patients on ART. For the primary outcomes of adherence and virological suppression, relative risks and 95% confidence intervals were calculated, and these were pooled using random effects meta-analysis. RESULTS: Twenty-one studies including information on 27,230 subjects were reviewed. Data from randomised trials showed better adherence among patients receiving FDCs than among patients who did not (relative risk 1.10, 95%CI 0.98-1.22); these findings were consistent with data from observational cohorts (RR 1.17, 95% CI 1.07-1.28). There was also a tendency towards greater virological suppression among patients receiving FDCs in randomised trials (RR 1.04, 95%CI 0.99-1.10) and observational cohort studies (RR 1.07, 95% CI 0.97-1.18). In all studies reporting patient preference, FDCs were preferred. The overall quality of the evidence was rated as low. CONCLUSIONS: Fixed-dose combinations appear to offer multiple advantages for programmes and patients, particularly with respect to treatment adherence.
Authors: Sheri D Weiser; Abigail M Hatcher; Lee L Hufstedler; Elly Weke; Shari L Dworkin; Elizabeth A Bukusi; Rachel L Burger; Stephen Kodish; Nils Grede; Lisa M Butler; Craig R Cohen Journal: AIDS Behav Date: 2017-02
Authors: Holly E Rawizza; Charlotte A Chang; Beth Chaplin; Isah A Ahmed; Seema T Meloni; Tinuade Oyebode; Bolanle Banigbe; Atiene S Sagay; Isaac F Adewole; Prosper Okonkwo; Phyllis J Kanki Journal: Curr HIV Res Date: 2015 Impact factor: 1.581
Authors: Leigh F Johnson; Olivia Keiser; Matthew P Fox; Frank Tanser; Morna Cornell; Chris J Hoffmann; Hans Prozesky; Andrew Boulle; Mary-Ann Davies Journal: AIDS Date: 2016-10-23 Impact factor: 4.177
Authors: Amitava Banerjee; Shweta Khandelwal; Lavanya Nambiar; Malvika Saxena; Victoria Peck; Mohammed Moniruzzaman; Jose Rocha Faria Neto; Katherine Curi Quinto; Andrew Smyth; Darryl Leong; José Pablo Werba Journal: Open Heart Date: 2016-09-14
Authors: Martina Penazzato; Devasena Gnanashanmugam; Pablo Rojo; Marc Lallemant; Linda L Lewis; Francesca Rocchi; Agnes Saint Raymond; Nathan Ford; Rohan Hazra; Carlo Giaquinto; Yodit Belew; Diana M Gibb; Elaine J Abrams Journal: Clin Infect Dis Date: 2017-06-01 Impact factor: 9.079
Authors: Ibrahim Dalhatu; Dennis Onotu; Solomon Odafe; Oseni Abiri; Henry Debem; Simon Agolory; Ray W Shiraishi; Andrew F Auld; Mahesh Swaminathan; Kainne Dokubo; Evelyn Ngige; Chukwuemeka Asadu; Emmanuel Abatta; Tedd V Ellerbrock Journal: PLoS One Date: 2016-11-09 Impact factor: 3.240
Authors: Inés Suárez-García; Belén Alejos; Marta Ruiz-Algueró; Cristina García Yubero; Cristina Moreno; Enrique Bernal; Laura Pérez-Is; Zuriñe Zubero; Miguel Alberto de Zárraga Fernández; Gloria Samperiz Abad; Inma Jarrín Journal: J Int AIDS Soc Date: 2021-07 Impact factor: 5.396